Lentivirus escape from neutralizing antibodies (NAbs) is not well understood. In this work, we quantified antibody escape of a lentivirus, using antibody escape data from horses infected with equine infectious anemia virus. We calculated antibody blocking rates of wild-type virus, fitness costs of mutant virus, and growth rates of both viruses. These quantitative kinetic estimates of antibody escape are important for understanding lentiviral control by antibody neutralization and in developing NAb-eliciting vaccine strategies.
U
nderstanding viral evasion of the immune response is essential to design effective vaccines against viral infections (1) (2) (3) (4) . Immune escape, and particularly antibody escape, is not well understood, partly because appropriate data sets that yield quantitative estimates of escape kinetics are rare (5) . Recently, studies of horses infected with equine infectious anemia virus (EIAV) have successfully documented antibody escape (6, 7) , thus providing a unique data set to examine the kinetics of antibody escape in a lentiviral infection. The goal of the present study was to estimate the strength of antibody pressure in this infection by determining how rapidly the virus escapes from the antibody response.
EIAV is a lentivirus that infects equids (8, 9) , has similarities to human immunodeficiency virus (HIV) (10) , and has served as a useful model to study lentiviral infection and immune escape (11) (12) (13) . In these studies, horses with severe combined immunodeficiency (SCID) were infected with EIAV after being infused with either plasma containing neutralizing antibodies (NAbs) from a persistently infected immunocompetent horse or plasma from uninfected normal controls. Frequent viral load measurements were taken for several weeks after virus challenge. Sequencing identified an identical neutralization-resistant viral variant (i.e., an escape mutant) in several NAb-infused horses (6, 7) . This variant was absent in control-infused horses. The escape of the variant was due solely to selection pressure of the passively transferred NAbs, because SCID horses do not have functional T or B cells to produce their own adaptive immune responses, including cytotoxic T lymphocytes (CTLs) (14, 15) .
We employed mathematical modeling and the data from EIAV infections of SCID horses (6, 7) to calculate the rate of viral escape due to antibody pressure. We also estimated the growth rates of wild-type and mutant viruses, the rate of antibody blocking of wild-type virus, the fitness cost of antibody escape, and the mutant growth advantage.
Previous studies have estimated the kinetics of CTL escape in HIV and simian immunodeficiency virus (SIV) infection (16) (17) (18) (19) (20) (21) (22) (23) (24) . Examination of antibody escape has begun (21, 25, 26) , but it has been less well studied due to the scarcity of antibody escape data. The current study provides quantitative kinetic estimates of antibody responses in lentiviral infection, which may have important implications for the control of other lentiviral infections (8, 27) and in the design of therapeutic strategies involving humoral responses.
We model the concentrations of EIAV WSU5 and EIAV WSU5-V55 as follows (5, 16, 18, 28, 29) :
For simplicity, we refer to the cell culture-adapted strain EIAV WSU5 of the virus inoculum as the wild type (w) and the neutralization-resistant variant EIAV WSU5-V55 as the mutant (m). Both viruses grow exponentially with net growth rates r and r(1 Ϫ c), respectively, where c is the fitness cost of the mutation (0 Յ c Ͻ 1). Wild-type virus is cleared by antibodies at rate a. The mutant is resistant to antibodies. The parameter represents mutation of the wild-type virus to the variant. We aimed to determine the values of these parameters by comparison with the equine data (Table 1) . Plasma viral load from 10 SCID horses experimentally infected with EIAV was measured by real-time quantitative RT-PCR, as described previously (6, 7) . Viral load measurements were taken beginning on the initial day of infection through peak infection with sampling every few days. As part of previous studies (6, 7) , horses A2245, A2247, H707, and H713 received infusions of irrelevant control antibodies from an uninfected immunocompetent horse; horses A2239, A2240, and H703 received infusions of NAbs from a persistently infected immunocompetent horse; horse H715 received lowdose infusions of NAbs; and horse A2274 received infusions of NAbs followed by heterologous virus challenge. Horse H727 served as the control for the heterologous challenge and received infusions of irrelevant control antibodies from an uninfected immunocompetent horse. Infusions were administered on days Ϫ1, 7, and 14 postinfection. All experiments involving animals in these previously published studies were approved by the Washington State University Institutional Animal Care and Use Committee. We refer to four groups of horses, groups I, II, III, and IV, for horses with control infusion (n ϭ 4), homologous challenge with physiological-dose NAb infusion (n ϭ 3), homologous challenge with low-dose NAb infusion (n ϭ 1), and heterologous challenge (n ϭ 1), respectively.
We first calculated the exponential growth rates for the wildtype and mutant virus in the absence of mutation ( ϭ 0). We determined the growth rate (r) of wild-type virus EIAV WSU5 , using a least-squares fit of the model to the viral load data of each of the four control-infused horses (group I) for which a was 0 ( Table 2 ).
The mean value was 58%/day. This gives a mean virus doubling time of 1.2 days ( Table 2) . We were able to calculate the growth rate r(1 Ϫ c) of neutralization-resistant variant EIAV WSU5-V55 from a 2-week period in horse A2239 (in group II), as during this time EIAV WSU5-V55 comprised 100% of the measured virus population. It may be noted that horse A2239 was the only animal that yielded data from which the neutralization-resistant variant growth rate could be calculated. Using least-squares data fitting again, the variant growth rate was 47%/day, giving a doubling time of 1.5 days ( Table 2) .
Given the growth rates, we calculated estimates for the antibody blocking rate, a, of the wild-type strain by comparing the growth rate of the wild type in the presence of antibody to its growth rate in the absence of antibody. We also determined the fitness cost (c), the growth advantage of the wild type in the absence of antibodies (rc), and the escape rate (ε ϭ a -rc). These calculations are shown in Table 3 . The growth advantage of the wild-type virus, calculated as the difference between the two growth rates [r Ϫ r(1 Ϫ c) ϭ rc], is 11%. The fitness cost of the escape mutation, c, is then 19%. Thus, the wild type dominates the mutant and has a growth advantage of 11% in the absence of antibody pressure. That is, the wild type grows faster than the mutant in the absence of antibody (a ϭ 0), and the mutant grows faster than the wild type in the presence of antibody [r Ͻ a, which follows from r Ϫ a Ͻ r(1 Ϫ c)]. The mean antibody blocking rate (a) is 63%. This implies that in less than 2 days, the wild type is completely blocked by antibody. Hence, the mean escape rate (ε ϭ a Ϫ rc) is 52%.
In the presence of antibodies, neutralization-resistant variant EIAV WSU5-V55 outgrew the wild type, EIAV WSU5 . We determined the mutant growth advantage of EIAV WSU5-V55 by calculating the absolute difference in growth rates of wild-type and mutant viruses in NAb-infused horses (group II) ( Table 4 ). The mean value was 33%/day. The implication here is that in the presence of NAbs and wild-type virus, the mutant virus becomes the prevalent population in 3 days on average. If we have the escape rate calculation (52%), then we can conclude more precisely that in 2 days, the mutant becomes the prevalent population.
In the absence of frequent viral load data, we could use amplicon data to calculate growth rates, assuming exponential growth between day 0 and the final day. Table 5 shows these calculations for wild-type virus growth. As expected, these coarser data underestimate growth rates substantially. However, we also note that if frequent viral load data are not available, amplicon data may be used as a proxy to give a minimal estimate for viral growth rates.
Another example of viral escape is given by group III horse H715, a case of homologous challenge but low-dose NAb protection (7). Here, virus inhibition was reduced with the lower dose of antibody. This horse showed a mixed viral population emerging, with 13/14 amplicons being wild-type EIAV WSU5 and 1/14 being the mutant EIAV WSU5-V55 (by single-genome amplification [SGA] and sequencing as described previously [6, 7] ). The antibody blocking rate (a) for this case was calculated to be 33%, nearly half that of physiological dose of NAb (Table 3 ). The escape rate was calculated to be 22%, remarkably lower than the rate obtained with the physiological dose of NAb (Table 3 ). The mutant growth advantage was calculated to be 1%/day, also substantially lower than that in the horses with the physiological dose of NAb (Table 4) . These results are consistent with the reasoning that a lower dose of neutralizing antibody exerts less antibody pressure, incompletely blocking the wild type and also permitting some outgrowth of the variant, resulting in lower values.
Group IV horse A2274 provides an example of virus growth for a physiological-dose NAb infusion but heterologous challenge. In this case, virus inhibition was reduced when antibody specificity was lower. This horse received NAbs from an EIAV WSU5 -infected immunocompetent horse but was challenged with EIAV PND5 , an EIAV molecular clone (27) , and a modest viral load was detected after 41 days (7) . While this experiment offers an example of inhibition by antibodies of a related EIAV strain, the viral load on day 41 could not be sequenced, so it is unknown whether the outgrowth was the index strain or a neutralization-resistant variant. We can, however, calculate estimates of escape kinetics in hypothetical cases. We used the growth rate (r) of 84% for controlinfused horse H727 infected with EIAV PND5 (Table 2) . If the emergent virus is the index strain EIAV PND5 , then the antibody inhibition (a) of the index strain is 42% ( Table 3 ), indicating that the heterologous antibody in the infusion was not high enough to inhibit wild-type infection. If the emergent virus is neutralization resistant, then the antibody inhibition (a) is 91% (Table 3) , the rate of escape is 75% (Table 3) , and the mutant growth advantage is calculated to be 50% (Table 4) . Such escape kinetics would be consistent with dynamics in which the antibody specificity of the NAbs (although mismatched to the virus) was sufficient to inhibit (6) . Horse A2239 (in group II) was NAb infused and infected with wild-type strain EIAV WSU5 (6) . Horse H727 was control infused and infected with molecular clone EIAV PND5 (7) . The virus inoculum given to horses in groups I and II contained a minority population of EIAV WSU5-V55 (6). On day 0, horses were inoculated with EIAV, and viral load (vRNA copies/ml) was measured every few days for several weeks (as indicated wild-type infection and exerted enough selection pressure to permit strong mutant escape. In spite of the limited data available, we were able to put forth calculations for EIAV antibody escape kinetics. Figure 1 shows these results, providing a comparison of antibody blocking, escape rate, and mutant growth advantage among the horses in groups II, III, and IV. We note that the variant growth rate calculation r(1 Ϫ c) was made based upon only one horse with available data, and this may impact the other parameters derived. Mutant growth advantage estimates were made using viral sequence data at peak infection, but these data were not available at other time points. Since amplicon values of zero pose a problem in these calculations, we replaced these with the lower limit of detection of the viral load assay as a fraction of the largest viral load value measured (430/10 7 vRNA copies/ml). This assumption is less coarse than that used in previous CTL escape rate studies that replaced zero values with 1/N or 1/(N ϩ 1), where N is the total number of amplicons (18, 20) . In the EIAV data set (6, 7), the total number of amplicons sequenced initially was greater than at the peak time point. Ideally, the same number of amplicons sequenced on the initial and final days would provide a more consistent calculation. The peak infection viral load sequence was not determined for horses H703 (presumed variant [6] ) and A2274 (indeterminate). Thus, our calculations for H703 rely upon the presumption that the virus was variant EIAV WSU5-V55 . For A2274, our results hold given that the index virus or the variant comprised the entire population on the final day, as specified.
Differences between the horses in groups III and IV (H715 and A2274) and those in group II could be attributable to several factors in addition to the dose of infusion (physiological or low) and the viral strain (EIAV WSU5 or EIAV PND5 ). These factors include that the horses in group III and IV were infused with purified plasma immunoglobulin rather than whole plasma and that the serum neutralization activity of group III and IV's donor horse was higher than that of group II's donor horse (7) . All group II horses received NAbs from persistently infected immunocompetent horse A2150, while group III and IV horses received NAbs from persistently infected immunocompetent horse A2140. All control animals (group I horses and horse H727) received infusions from the same uninfected horse.
We have taken the case without mutation ( ϭ 0) in this work. The mutation rate of EIAV is not known, but if we assume it to be equivalent to that of HIV [ ϭ 3 ϫ 10 Ϫ5 /(base · cycle)] (30), we note that our results change negligibly. Since variant EIAV WSU5-V55 was present in the inoculum, it is not possible to distinguish if its emergence was due to outgrowth of a very small population or a new mutation event. Furthermore, it may be that some or all the infused antibody had decayed by the time the variant population was measurable.
The SCID horse data match data from immunocompetent horses well. In immunocompetent horses, the EIAV viral genome evolves continuously throughout the various stages of infection (31) . Detailed quasispecies analyses have been performed in experimentally infected horses and showed that new viral strains emerge, completely replacing earlier isolates, and correlating with clinical disease episodes (31) (32) (33) (34) (35) (36) (37) (38) . These antigenic variants arise as a result of selective pressure from immune responses, including antibodies (8, 27, 31) . Thus, the infected SCID horse data are not unexpected compared to those from immunocompetent horses, in that the variant emergence in NAb-infused SCID horses was seen within 2 months of infection.
In summary, this study provides estimates of antibody escape kinetics in SCID horses infected with EIAV. We estimated rates of viral growth, antibody blocking, antibody escape, and growth advantage for physiological and low doses of NAbs and showed that more rapid escape occurs with greater antibody blocking. Our estimates show that the growth rate of EIAV WSU5 (58%; doubling time, 1.2 days) is greater than the growth rate of neutralizationresistant variant EIAV WSU5-V55 (47%; doubling time, 1.5 days) but lower than that of molecular clone EIAV PND5 (84%; doubling time, 0.8 days) ( Table 2) . Despite a lower growth rate, with selective antibody pressure the variant overtook the wild-type virus 52%/day (Table 3 ). This study found that estimates of mutant growth advantage (Table 4) are lower than escape rate estimates (Table 3) for both physiological-dose NAbs and low-dose NAbs. 
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a The mean value of r is 58% from Table 2 . The mutant growth rate r(1-c) was calculated by fitting the dm/dt equation to A2239 data from day 41 to 55, when singlegenome amplification (SGA) and sequencing showed 100% variant EIAV WSU5-V55 at both time points (as in Table 2 ). From this we calculated c using the average r. The growth advantage of the wild type is r Ϫ r(1 Ϫ c) ϭ rc in the absence of antibody. When antibody is present, the growth rate of the wild type is r Ϫ a. The antibody blocking rate, a, is thus obtained from [r Ϫ (r Ϫ a)]. It is only when antibodies against the wild type are present that mutant escapes. This escape rate is calculated as ε ϭ r(1 Ϫ c) Ϫ (r Ϫ a) ϭ a Ϫ rc. WT, wild type. b While SGA was not possible on day 33 vRNA from H703, postmortem analysis identified the variant EIAV WSU5-V55 provirus by PCR and sequencing. Thus, H703 calculations were performed presuming that 7/7 amplicons were variant EIAV WSU5-V55 . c Horse A2274 was infected with molecular clone EIAV PND5 . Calculations with A2274 are only speculative, since the sequence of the emergent virus at day 41 is unknown. This calculation assumed that day 41 virus was an escape variant. We used the corresponding value for r (in Table 2 ) from horse H727, the control-infused horse infected with EIAV PND5 . The fitness cost of the putative variant is unknown, so for the escape rate calculation we assumed that c is the same as for EIAV WSU5-V55 . d Horse A2274 was infected with molecular clone EIAV PND5 . Calculations with A2274 are only speculative, since the sequence of the emergent virus at day 41 is unknown. This calculation assumed that day 41 virus was index strain EIAV PND5 . We used the corresponding value for r (in Table 2 ) from horse H727, the control-infused horse infected with EIAV PND5 .
Furthermore, the estimated antibody blocking at physiological dose by heterologous NAbs (42%, assuming that the emergent virus was the index strain) is lower than that by homologous NAbs (63%), as may be expected. Heterologous NAb blocking was higher than blocking with low-dose homologous NAbs (33%) ( Table 3 ). The implication of this is that a higher dosage can overcome lower or mismatched NAb specificity. With more abundant data and the same method, one could provide better estimates of model parameters. In particular, it would be very useful to obtain more accurate estimates of the strength of antibody needed to block infection. The results of this study are consistent with earlier theoretical work by Coffin (39) , which predicted that relatively small changes in selective pressure and viral fitness can result in rapid and profound changes in the composition of the virus population in vivo. We showed that in the EIAV-infected SCID horses, although the viral variant has a lower growth rate, selective pressure against the index strain could allow the variant to emerge as the dominant population. In this work, we quantified this result by measuring the antibody escape kinetics in a simple system with two viral species. Our results are also consistent with studies of CTL escape kinetics in HIV infection as summarized by Perelson and Ribeiro (5) . They describe how the escape rate changes in proportion to killing of the wild type by CTLs, and predictably, the fastest escapes would be seen when selective pressure from CTLs is high. Here, we found that the antibody escape rate for EIAV in SCID horses decreases in proportion to antibody blocking, as might be expected. Specifically, the escape rate was much lower (22%) for horse H715, which had low-dose antibody infusions, than the escape rate in horses with physiological-dose antibody infusions (mean value, 52%). We also found that the antibody escape rate decreases in proportion to the mutant growth advantage. In conclusion, knowledge of antibody escape kinetics in lentiviral infection will increase our understanding of antibody control and how we might develop vaccine strategies that include neutralizing antibodies. (6) . Horse H715 was administered a low-dose NAb infusion and infected with wild-type strain EIAV WSU5 (7) . Horse A2274 was NAb infused and infected with molecular clone EIAV PND5 (7), representing heterologous challenge, because the donor horses that provided the NAbs had been infected with EIAV WSU5 . b The fraction of samples represents the number of amplicons with the indicated sequence out of the total number of amplicons sequenced (6, 7) . In the inoculum, one amplicon showed the sequence of the variant EIAV WSU-V55 . Note that the initial number of samples is larger than the final number of samples. Final day represents peak infection and the time when single-genome amplification (SGA) was performed. For horse A2239, SGA was performed on days 41 and 55; calculations shown used day 41 as the final day. c The mutant growth advantage (which is the absolute difference between growth rates of the mutant and the wild type) for each horse was estimated from the fraction of amplicons of each sequence present at the initial and final day of the time interval, as in previous studies of immune escape (18, 20, 25) . The mutant has a growth advantage only in the presence of antibody. In these calculations, in cases in which zero amplicons of a particular sequence were observed at a given time point, zero values were replaced with the lower limit of detection of viral load, which is 430 viral RNA copies/ml (6), as a fraction of the upper limit of 10 7 viral RNA copies/ml, since this was the highest viral load measured in the horses. Thus, the cases where zero amplicons showed virus for a particular sequence were set to 430/10 7 (or 0.000043) viral RNA copies/ml. Cases where 100% of amplicons showed a particular sequence were set to 100 Ϫ 0.000043. d While SGA was not possible on day 33 vRNA from H703, postmortem analysis identified the variant EIAV WSU5-V55 provirus by PCR and sequencing (6) . Thus, H703 calculations were performed presuming that 7/7 amplicons were variant EIAV WSU5-V55 . e Assuming that day 41 virus is an escape variant. Calculations with A2274 are only speculative, since we do not know the sequence of the emergent virus at day 41. The initial virus is 100% EIAV PND5 . 
